相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy
Andrea Messori
CLINICAL DRUG INVESTIGATION (2016)
Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK
Virginia Becerra et al.
BMJ OPEN (2015)
Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
Alex McConnachie et al.
EUROPEAN HEART JOURNAL (2014)
Resistance and intolerance to statins
Z. Reiner
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2014)
Changes to the Statin Prescribing Policy in Belgium
Danny Liew et al.
American Journal of Cardiovascular Drugs (2013)
How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?
Patricia Maningat et al.
CURRENT ATHEROSCLEROSIS REPORTS (2013)
Cardiovascular Disease in the Developing World
David S. Celermajer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
R. Ara et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2012)
Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain
Vivencio Barrios et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany
Galin V. Michailov et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2012)
ESC/EAS GUIDELINES ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2011)
Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial
Robert L. Ohsfeldt et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis
J. P. Greving et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
EUROPEAN HEART JOURNAL (2011)
The Cost Effectiveness of Statin Therapies in Spain in 2010, after the Introduction of Generics and Reference Prices
Pedro Plans-Rubio
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2010)
Predictors of Nonadherence to Statins: A Systematic Review and Meta-Analysis
Devin M. Mann et al.
ANNALS OF PHARMACOTHERAPY (2010)
Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland
Erkki J. O. Soini et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden
Janne A. Martikainen et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia
L. Nherera et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial
Paula K. Lorgelly et al.
EUROPEAN JOURNAL OF HEART FAILURE (2010)
Modeling in pharmacoeconomic studies: Funding sources and outcomes
Livio Garattini et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2010)
Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study
John Reckless et al.
VALUE IN HEALTH (2010)
Continuation of Statin Treatment and All-Cause Mortality A Population-Based Cohort Study
Varda Shalev et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study
Douglas C. A. Taylor et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2009)
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
J. J. Brugts et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men
Piia Peura et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Edward J. Mills et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal
Carlos Gouveia Pinto et al.
VALUE IN HEALTH (2008)
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
Peter Lindgren et al.
EUROPEAN HEART JOURNAL (2007)
European guidelines on cardiovascular disease prevention in clinical practice: Full text
Ian Graham et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2007)
The cost-effectiveness of fluvastatin in hungary following successful percutaneous coronary intervention
Paul A. Scuffham et al.
CARDIOVASCULAR DRUGS AND THERAPY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Long-term persistence in use of statin therapy in elderly patients
JS Benner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
分享论文
